Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

(MedPage Today) -- A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic suppression compared with standard daily oral treatment in an open-label phase II trial. In 104 virologically...

Newswise Latest News: news and press releases in science, medicine, life, and business

A phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV found that ISL+LEN maintained high rates of virologic suppression through 48 weeks, with no treatment-related grade 3 or greater adverse events or serious adverse events.